Letrozole Tablet, Film Coated
Product Images NDC 51407-986

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 51407-986). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)
FDA Label Image

51407-986-90lb Rev. 04-25 .jpg (51407 986 90lb Rev. 04 25)

51407-986-90lb Rev. 04-25 .jpg (51407 986 90lb Rev. 04 25)
This text appears to be labeling information for a medication in tablet form containing 2.5 mg of a substance. It includes dosage instructions, storage recommendations, a caution to keep medications out of reach of children, and the market details of the product. The tablets mentioned are indicated to contain FD&C Yellow No.5 (tartrazine) as a color additive. It is manufactured by GSMS, Incorporated and the information is dated as revised on 04/25.*
FDA Label Image

Figure-1 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)

Figure-1 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)
FDA Label Image

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)
Not available.*
FDA Label Image

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)
FDA Label Image

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)
This is a description of Figure 4 showing Kaplan-Meier Estimates of Time to Progression in the Megestrol Acetate Study. It likely presents survival analysis data related to the progression of a condition or disease in a study involving megestrol acetate.*
FDA Label Image

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)
This text provides a figure description for Kaplan-Meier Estimates of Time to Progression in the Aminoglutethimide Study. It likely includes data on the progression of a specific condition or disease over time and may be used to evaluate the effectiveness of a treatment or intervention.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.